Skip to main content
Top
Published in: Diabetologia 4/2003

01-04-2003 | Short Communication

Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy

Authors: R. C. Nayak, PhD, C. D. Agardh, M. G. K. Kwok, H. Stjernquist, P. J. Farthing-Nayak, E. Agardh

Published in: Diabetologia | Issue 4/2003

Login to get access

Abstract

Aims/Hypothesis

This study aims to determine the prevalence of anti-pericyte autoantibodies in Type 2 diabetes and to characterize these autoantibodies as new markers of disease activity in diabetic retinopathy.

Methods

A total of 299 patients with Type 2 diabetes participated in this study. Retinopathy was assessed by 7-field stereo fundus photography and was graded according to the ETDRS scale. Serum anti-pericyte autoantibodies were detected by immunofluorescence on tissue cultured bovine retinal pericytes.

Results

The prevalence of anti-pericyte autoantibodies in Type 2 diabetic patients was 54% and was approximately equal in men and women. The prevalence was approximately 55% with retinopathy at grades from 10 to 53. At grades above 53 the prevalence declined to 23% (p<0.0001). The highest prevalence by duration of diabetes, 70%, was found at 0 to 5 years and the lowest, 25% at more than 25 years duration (p<0.0001).

Conclusion/interpretation

Anti-pericyte autoantibodies are present at high prevalence in Type 2 diabetes. Their presence during earlier stages of retinopathy could be due to a reaction with antigens expressed by "activated" pericytes. The decline in antibody prevalence in advanced retinopathy could mark pericyte loss and progression to an angiogenic retinal milieu.
Literature
1.
go back to reference Attawia MA, Nayak RC (1999) Circulating antipericyte autoantibodies in diabetic retinopathy. Retina 19:390–400PubMed Attawia MA, Nayak RC (1999) Circulating antipericyte autoantibodies in diabetic retinopathy. Retina 19:390–400PubMed
2.
go back to reference Anonymous (1997) World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926PubMed Anonymous (1997) World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926PubMed
3.
go back to reference Anonymous (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98 [Suppl 5]:823–833 Anonymous (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98 [Suppl 5]:823–833
4.
go back to reference Nayak RC, Herman IM (2001) Bovine Retinal Microvascular Pericytes: Isolation, Propagation and Identification, In: Murray C (ed.) Methods in molecular medicine: angiogenesis protocols. Humana Press Inc., Totowa, pp 247–263 Nayak RC, Herman IM (2001) Bovine Retinal Microvascular Pericytes: Isolation, Propagation and Identification, In: Murray C (ed.) Methods in molecular medicine: angiogenesis protocols. Humana Press Inc., Totowa, pp 247–263
5.
go back to reference Dodge AB, D'Amore PA (1992) Cell-cell interactions in diabetic angiopathy Diabetes Care 15:1168–1180 Dodge AB, D'Amore PA (1992) Cell-cell interactions in diabetic angiopathy Diabetes Care 15:1168–1180
6.
go back to reference Harris MI, Klein R, Welborn TA et al. (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819PubMed Harris MI, Klein R, Welborn TA et al. (1992) Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819PubMed
Metadata
Title
Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy
Authors
R. C. Nayak, PhD
C. D. Agardh
M. G. K. Kwok
H. Stjernquist
P. J. Farthing-Nayak
E. Agardh
Publication date
01-04-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1057-0

Other articles of this Issue 4/2003

Diabetologia 4/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine